We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
109 hedge funds and large institutions have $151M invested in Lineage Cell Therapeutics in 2017 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 21 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
71% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 21
14% more funds holding
Funds holding: 96 → 109 (+13)
1.33% more ownership
Funds ownership: 48.18% → 49.51% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less capital invested
Capital invested by funds: $161M → $151M (-$9.93M)
27% less call options, than puts
Call options by funds: $112K | Put options by funds: $153K
Holders
109
Holders Change
+13
Holders Change %
+13.54%
% of All Funds
2.72%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
36
Reduced
21
Closed
7
Calls
$112K
Puts
$153K
Net Calls
-$41K
Net Calls Change
+$59K
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.71M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$582K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$488K |
| 4 |
Two Sigma Investments
New York
|
+$441K |
| 5 |
IA
IndexIQ Advisors
New York
|
+$438K |
Top Sellers
| 1 |
Northern Trust
Chicago,
Illinois
|
-$1.8M |
| 2 |
Millennium Management
New York
|
-$362K |
| 3 |
Jane Street
New York
|
-$223K |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$196K |
| 5 |
Goldman Sachs
New York
|
-$181K |
